CRB Inverbío
VC Fund
Madrid, Spain
CRB Inverbío is a venture capital management firm registered with number 87 in the CNMV. CRB Inverbío manages Venture Capital Firms that invest in the development of seed-stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses. To that end, the company selects innovative projectsled by prestigious scientists and entrepreneurs, providing financing, management support and strategic advice.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $70M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CRB Inverbío invests in
Stages CRB Inverbío invests in
Countries CRB Inverbío invests in
Round sizes
Round size
- Seed
- $3.3M–$5.3M
- Series A
- $2.2M–$8.9M
Investment Focus
Industry
- Health Care 9 (56%)
- Medical 8 (50%)
- Biotechnology 7 (44%)
- Medical Device 4 (25%)
- Biopharma 2 (13%)
Stage
- Series A 6 (38%)
- Funding Round 4 (25%)
- Seed 2 (13%)
- Grant 1 (6%)
- Series B 1 (6%)
Country
- Spain 9 (56%)
- Italy 1 (6%)
- Mexico 1 (6%)
- United Kingdom 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Prosoma
|
Prosoma was born out a need to provide more comprehensive care for cancer patients. We have found a fundamental lack of access to psychological care for patients who not only have to face a life-altering disease and treatment, but also crucially have a different set of needs than other psychological patients. Barriers to accessing psychologicalcare often include low numbers of therapists and clinicians in the area, financial or geographical limitations, and the general wellbeing of patients preventing them from attending meetings. All of these issues can be solved by modern technology.By using VR as part of, or when necessary, an alternative to traditional psychological treatment, we can reach patients that would otherwise be left without any support. They can use our tool at home or in the clinics whilst undergoing pharmacological treatment and chemotherapy.We hope to provide patients with a tool that will help them manage stress, cope with the burden of cancer, and eventually improve their quality of life. | Series A / Jun 16, 2025 | |
Carol
|
Carol is a tech-enabled healthcare provider delivering membership-based primary care services, on a mission to make high-quality healthcare accessible and affordable for everyone. To achieve this goal, Carol leverages a highly scalable technology, combined with high quality clinical operations and a salaried provider model. | $5.3M / Seed / May 30, 2024 | |
Nuubo
|
Nuubo is a Spanish medical device company that develops wireless, wearable technologies to monitor physiological parameters. To do so, Nuubo has a platform known as nECG DYNAMIC PLATFORM, which makes it easier to perform and read an electrocardiogram remotely. Specifically, the system patented by Nuubo is made up of three elements: a biomedicalgarment that allows the electrocardiogram signal to be captured without interfering with the patient’s daily activity; a device that continuously records the information captured by the garment and which also allows the data to be sent wirelessly and in real time for processing; and analysis and visualization software that, using artificial intelligence algorithms, can interpret all of the information transmitted by the wireless device.The devices designed by Nuubo allow patients’ hearts to be monitored for longer periods of time and without feeling uncomfortable or intrusive. The company is headquartered in Madrid, Spain. | Venture - Series Unknown / Dec 23, 2022 | |
|
Nuubo
|
Nuubo is a Spanish medical device company that develops wireless, wearable technologies to monitor physiological parameters. To do so, Nuubo has a platform known as nECG DYNAMIC PLATFORM, which makes it easier to perform and read an electrocardiogram remotely. Specifically, the system patented by Nuubo is made up of three elements: a biomedicalgarment that allows the electrocardiogram signal to be captured without interfering with the patient’s daily activity; a device that continuously records the information captured by the garment and which also allows the data to be sent wirelessly and in real time for processing; and analysis and visualization software that, using artificial intelligence algorithms, can interpret all of the information transmitted by the wireless device.The devices designed by Nuubo allow patients’ hearts to be monitored for longer periods of time and without feeling uncomfortable or intrusive. The company is headquartered in Madrid, Spain. | $262.2K / Venture - Series Unknown / Oct 10, 2022 | |
Biocross
|
Biocross, S.L., a biotechnology company, develops blood tests for the diagnosis of Alzheimer’s diseases to neurologists. | $494K / Sep 01, 2021 | |
|
Biocross
|
Biocross, S.L., a biotechnology company, develops blood tests for the diagnosis of Alzheimer’s diseases to neurologists. | $532.9K / Grant / Sep 01, 2021 | |
Aglaris Ltd
|
Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells.Aglaris produces equipment to ensure cell and tissue culture is an easy, problem-free task. By automating and controlling the cell culture processes, we can obtain cells and tissues with sufficient quality to revitalize regenerative medicine andcell therapies. The technology used by our equipment is unique and is protected by international patents. | $2.2M / Series A / Mar 01, 2016 | |
Iden Biotechnology
|
Iden biotechnology is a scientific company, whose main activity is the generation, transfer, exploitation, and marketing of biotechnological knowledge. They are a technology transfer company matching market demands with biotechnology research developments from universities and technology centers. Their main target is to increase the transfer ofquality technology from academia to industry. | $4.2M / Series A / Feb 24, 2015 | |
Mecwins
|
Mecwins uses its own technology to produce ultra-high sensitive immunoassays for oncology, cardiovascular and infectious diseases. | $4.4M / Series A / Jun 05, 2014 | |
|
Nuubo
|
Nuubo is a Spanish medical device company that develops wireless, wearable technologies to monitor physiological parameters. To do so, Nuubo has a platform known as nECG DYNAMIC PLATFORM, which makes it easier to perform and read an electrocardiogram remotely. Specifically, the system patented by Nuubo is made up of three elements: a biomedicalgarment that allows the electrocardiogram signal to be captured without interfering with the patient’s daily activity; a device that continuously records the information captured by the garment and which also allows the data to be sent wirelessly and in real time for processing; and analysis and visualization software that, using artificial intelligence algorithms, can interpret all of the information transmitted by the wireless device.The devices designed by Nuubo allow patients’ hearts to be monitored for longer periods of time and without feeling uncomfortable or intrusive. The company is headquartered in Madrid, Spain. | $3.3M / May 30, 2014 | |
| See all 16 investments → | |||
Co-Investors
Centre for the Development of Industrial Technology (CDTI)
4 deals together
Criteria Venture Tech
2 deals together
Clave Mayor
2 deals together
Aligo Venture Capital
1 deal together
AXIS Participaciones Empresariales
1 deal together
Biozell Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CRB Inverbío invest in?
CRB Inverbío invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 16 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is CRB Inverbío's check size?
CRB Inverbío typically joins rounds of $3.3M–$5.3M at Seed and $2.2M–$8.9M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CRB Inverbío participates in.
When did CRB Inverbío last invest?
The most recent investment recorded for CRB Inverbío closed in Jun 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
